RSV Vaccination for Your 69-Year-Old Patient
Your 69-year-old patient should receive a single dose of RSV vaccine if they have any increased risk factors for severe RSV disease, including chronic heart disease, chronic lung disease, diabetes, end-stage renal disease, severe obesity, moderate/severe immunocompromise, or residence in a nursing home. 1
Current ACIP Recommendations (2024)
The most recent ACIP guidelines from June 2024 provide clear age-stratified recommendations:
- All adults ≥75 years: Universal RSV vaccination recommended
- Adults 60-74 years: RSV vaccination recommended only if they have increased risk factors for severe disease 1
Since your patient is 69 years old, vaccination depends entirely on their risk profile.
Risk Factors That Qualify for Vaccination (Ages 60-74)
Your patient qualifies for RSV vaccination if they have any of the following conditions 1, 2:
- Chronic cardiovascular disease (particularly heart failure)
- Chronic lung/respiratory disease (COPD, asthma, bronchiectasis, interstitial lung disease)
- End-stage renal disease
- Diabetes mellitus
- Neurologic/neuromuscular conditions
- Chronic liver disease
- Chronic hematologic conditions
- Severe obesity (BMI ≥30 in some guidelines)
- Moderate to severe immunocompromise (including cancer, immunosuppressive medications, transplant recipients)
- Residence in a nursing home or long-term care facility
Why This Matters: Disease Burden
RSV is a major cause of respiratory illness, hospitalization, and death in older adults 1. The evidence demonstrates:
- Vaccine effectiveness of 75.1% against RSV-associated acute respiratory infection in real-world data 3
- 58% effectiveness against RSV-associated hospitalization across two seasons 4
- 69% effectiveness when vaccinated in the same season, declining to 48% in the subsequent season 4
Important caveat: Effectiveness is lower in immunocompromised patients (30% vs 67% in immunocompetent adults) and those with cardiovascular disease (56% vs 80% without) 4. However, these high-risk groups still benefit and are precisely the populations for whom vaccination is recommended.
Vaccine Options
Three FDA-approved vaccines are available 1:
- Arexvy (GSK) - protein subunit vaccine
- Abrysvo (Pfizer) - protein subunit vaccine
- mResvia (Moderna) - mRNA vaccine
All are given as a single dose and provide protection for at least two RSV seasons 1.
Timing
Administer the vaccine in late summer or early fall (August-October) for maximum benefit before RSV season begins 1. However, eligible patients who haven't been vaccinated can receive it at any time of year.
Safety Considerations
The vaccines are generally well-tolerated. Key safety findings from postlicensure surveillance 3:
- No excess risk of immune thrombocytopenic purpura
- Small elevated risk of Guillain-Barré syndrome with RSVPreF (Abrysvo): 18.2 excess cases per 1,000 doses
- No elevated GBS risk detected with RSVPreF3+AS01 (Arexvy)
The absolute risk remains very small, and the benefits in preventing severe RSV disease outweigh these risks in eligible populations.
Clinical Decision Algorithm
For your 69-year-old patient:
- Review their medical history for any of the risk factors listed above
- If ANY risk factor is present: Recommend RSV vaccination 1
- If NO risk factors present: Vaccination is not currently recommended; reassess when they turn 75
- If already vaccinated: Do not give another dose 1
Common Pitfall to Avoid
The 2023 recommendation used "shared clinical decision-making" for all adults ≥60 years, which created implementation barriers and confusion 1. The updated 2024 guidance eliminates this ambiguity for the 60-74 age group by clearly defining who should be vaccinated based on risk factors. Don't default to shared decision-making—if your patient has qualifying risk factors, vaccination is recommended, not optional 1.